Profile change history

What changed for Cagrilintide?

A deterministic history of records added to PeptideScanner and preserved profile or record revisions connected through the reviewed Cagrilintide identity.

17Total events
14Record additions
3Version changes
4Cited source years

Source-published notices

Research integrity notices

Method and complete cohort →

Before and after

Preserved version changes

Record updated

ClinicalTrials.gov record NCT07220759

ClinicalTrials.gov posted a newer version of NCT07220759, with a registry update date of 2026-11-16. This version reports that observation; the earlier retained observation remains available as version 1.

PeptideScanner change date
November 16, 2026
Cited source date
November 16, 2026
Evidence lane
Clinical trials

Summary

Before
PeptideScanner retained ClinicalTrials.gov record NCT07220759 at 2026-08-13T05:52:27.019Z. Its registry update date was 2026-08-03, and PeptideScanner's reviewed identity mapping was cagrilintide.
After
PeptideScanner retained ClinicalTrials.gov record NCT07220759 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was cagrilintide.

Cited source date

Before
2026-08-03
After
2026-11-16

Source observed date

Before
2026-08-13
After
2026-11-16

Cited source records

Before
ctg-observation-nct07220759-2026-08-03-50fb10a6adbd
After
ctg-observation-nct07220759-2026-08-03-50fb10a6adbd-r2

Headline citations

Before
ctg-observation-nct07220759-2026-08-03-50fb10a6adbd
After
ctg-observation-nct07220759-2026-08-03-50fb10a6adbd-r2

Summary citations

Before
ctg-observation-nct07220759-2026-08-03-50fb10a6adbd
After
ctg-observation-nct07220759-2026-08-03-50fb10a6adbd-r2

Attributable context

Before
1. PeptideScanner retained ClinicalTrials.gov record NCT07220759 at 2026-08-13T05:52:27.019Z. Its registry update date was 2026-08-03, and PeptideScanner's reviewed identity mapping was cagrilintide. [sources: ctg-observation-nct07220759-2026-08-03-50fb10a6adbd] 2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct07220759-2026-08-03-50fb10a6adbd]
After
1. PeptideScanner retained ClinicalTrials.gov record NCT07220759 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was cagrilintide. [sources: ctg-observation-nct07220759-2026-08-03-50fb10a6adbd-r2] 2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct07220759-2026-08-03-50fb10a6adbd-r2]

Source snapshot commitment

Before
25fdc0e1abb2c8ef471c57c54351ee7c4138fb59866fb3a21639ee2b2a876300
After
9223ed410ea30b6c045445fd7c2ca6ef3168ef01beef2c6fcaf1fa4c392ff10e
Profile status changed

Cagrilintide profile

We added a plain-language reader guide with cited answers, published trial results from our human evidence review, current ClinicalTrials.gov records, and FDA’s current page on unapproved GLP-1 drugs (content current as of October 1, 2026), which states that cagrilintide cannot be used in compounding.

PeptideScanner change date
November 14, 2026
Evidence lane
Profile

Status

Before
Investigational
After
In clinical trials; not FDA-approved

Profile summary

Before
A long-acting amylin analogue under study. This profile cites a recruiting ClinicalTrials.gov record.
After
An experimental long-acting amylin analogue from Novo Nordisk, studied alone and combined with semaglutide as CagriSema. FDA says it is not an approved drug and cannot be used in compounding.

Evidence note

Before
ClinicalTrials.gov lists a Novo Nordisk pediatric study as recruiting, updated July 17, 2026.
After
A published Phase 2 trial of cagrilintide alone and large Phase 3 trials of the cagrilintide-semaglutide combination report weight loss; combination results cannot be credited to cagrilintide alone. FDA states that cagrilintide has not been found safe and effective for any condition.

Related names

Before
AM833
After
AM833, CagriSema

Cited source records

Before
ctg-nct07253285-v5
After
ctg-nct07253285-v5, fda-unapproved-glp1-concerns-2026-r2, journal-pmid-34798060, journal-pmid-40544433, ctg-observation-nct07220759-2026-08-03-50fb10a6adbd, ctg-observation-nct07745504-2026-08-04-624035118e08

Named organizations

Before
Novo Nordisk A/S [sources: ctg-nct07253285-v5]
After
Novo Nordisk A/S [sources: ctg-nct07253285-v5]; U.S. Food and Drug Administration [sources: fda-unapproved-glp1-concerns-2026-r2]

Claim citations

Before
name: ctg-nct07253285-v5; aliases: ctg-nct07253285-v5; category: ctg-nct07253285-v5; status: ctg-nct07253285-v5; summary: ctg-nct07253285-v5; evidenceNote: ctg-nct07253285-v5
After
name: ctg-nct07253285-v5; aliases: ctg-nct07253285-v5, journal-pmid-40544433; category: ctg-nct07253285-v5; status: ctg-nct07253285-v5, ctg-observation-nct07220759-2026-08-03-50fb10a6adbd, fda-unapproved-glp1-concerns-2026-r2; summary: journal-pmid-34798060, journal-pmid-40544433, fda-unapproved-glp1-concerns-2026-r2; evidenceNote: journal-pmid-34798060, journal-pmid-40544433, fda-unapproved-glp1-concerns-2026-r2
Profile updated

Cagrilintide profile

We rewrote the profile summary to describe the cited study record more directly. The cited source and status did not change.

PeptideScanner change date
July 27, 2026
Evidence lane
Profile

Profile summary

Before
A long-acting amylin analogue represented in ongoing ClinicalTrials.gov records.
After
A long-acting amylin analogue under study. This profile cites a recruiting ClinicalTrials.gov record.

Collection chronology

Evidence added to PeptideScanner

Browse all 14 connected records →

Showing the latest 14 additions by PeptideScanner publication date; the complete connected record set remains available on the cross-source timeline. Most recent addition: September 9, 2026.

Record added

ClinicalTrials.gov record NCT07411560

PeptideScanner retained ClinicalTrials.gov record NCT07411560 at 2026-07-30T16:20:49.304Z. Its registry update date was 2026-04-13, and PeptideScanner's reviewed identity mapping was cagrilintide.

PeptideScanner change date
September 9, 2026
Cited source date
April 13, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07607587

PeptideScanner retained ClinicalTrials.gov record NCT07607587 at 2026-07-30T16:19:03.059Z. Its registry update date was 2026-06-25, and PeptideScanner's reviewed identity mapping was cagrilintide.

PeptideScanner change date
September 9, 2026
Cited source date
June 25, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07220759

PeptideScanner retained ClinicalTrials.gov record NCT07220759 at 2026-08-13T05:52:27.019Z. Its registry update date was 2026-08-03, and PeptideScanner's reviewed identity mapping was cagrilintide.

PeptideScanner change date
August 14, 2026
Cited source date
August 3, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07745504

PeptideScanner retained ClinicalTrials.gov record NCT07745504 at 2026-08-13T05:52:27.004Z. Its registry update date was 2026-08-04, and PeptideScanner's reviewed identity mapping was cagrilintide.

PeptideScanner change date
August 14, 2026
Cited source date
August 4, 2026
Evidence lane
Clinical trials
Record added

PubMed record PMID 40609154

PeptideScanner retained PubMed bibliographic metadata for PMID 40609154 at 2026-07-30T18:24:19.064Z. PubMed recorded a metadata revision date of 2025-08-26 and an Entrez history date of 2025-07-03. PeptideScanner associated this retained record with the identity slug cagrilintide. These dates describe PubMed metadata history, not the article's original publication date.

PeptideScanner change date
August 11, 2026
Cited source date
August 26, 2025
Evidence lane
Literature metadata
Record added

PubMed record PMID 40847076

PeptideScanner retained PubMed bibliographic metadata for PMID 40847076 at 2026-07-30T16:31:19.891Z. PubMed recorded a metadata revision date of 2026-01-06 and an Entrez history date of 2025-08-22. PeptideScanner associated this retained record with the identity slug cagrilintide. These dates describe PubMed metadata history, not the article's original publication date.

PeptideScanner change date
August 11, 2026
Cited source date
January 6, 2026
Evidence lane
Literature metadata
Record added

PubMed record PMID 36242844

PeptideScanner retained PubMed bibliographic metadata for PMID 36242844 at 2026-07-30T19:34:05.168Z. PubMed recorded a metadata revision date of 2022-11-29 and an Entrez history date of 2022-10-15. PeptideScanner associated this retained record with the identity slug cagrilintide. These dates describe PubMed metadata history, not the article's original publication date.

PeptideScanner change date
August 10, 2026
Cited source date
November 29, 2022
Evidence lane
Literature metadata
Record added

PubMed record PMID 39868309

PeptideScanner retained PubMed bibliographic metadata for PMID 39868309 at 2026-07-30T16:14:10.807Z. PubMed recorded a metadata revision date of 2026-06-25 and an Entrez history date of 2025-01-27. PeptideScanner associated this retained record with the identity slug cagrilintide. These dates describe PubMed metadata history, not the article's original publication date.

PeptideScanner change date
August 10, 2026
Cited source date
June 25, 2026
Evidence lane
Literature metadata
Record added

PubMed record PMID 40204768

PeptideScanner retained PubMed bibliographic metadata for PMID 40204768 at 2026-07-30T18:29:52.187Z. PubMed recorded a metadata revision date of 2025-04-12 and an Entrez history date of 2025-04-09. PeptideScanner associated this retained record with the identity slug cagrilintide. These dates describe PubMed metadata history, not the article's original publication date.

PeptideScanner change date
August 10, 2026
Cited source date
April 12, 2025
Evidence lane
Literature metadata
Record added

PubMed record PMID 42260118

PeptideScanner retained PubMed bibliographic metadata for PMID 42260118 at 2026-07-30T16:14:18.129Z. PubMed recorded a metadata revision date of 2026-06-25 and an Entrez history date of 2026-06-08. PeptideScanner associated this retained record with the identity slug cagrilintide. These dates describe PubMed metadata history, not the article's original publication date.

PeptideScanner change date
August 10, 2026
Cited source date
June 25, 2026
Evidence lane
Literature metadata
Record added

ClinicalTrials.gov record NCT05804162

PeptideScanner retained ClinicalTrials.gov record NCT05804162 at 2026-07-30T18:38:25.523Z. Its registry update date was 2024-11-01, and PeptideScanner's reviewed identity mapping was cagrilintide.

PeptideScanner change date
August 9, 2026
Cited source date
November 1, 2024
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07557953

PeptideScanner retained ClinicalTrials.gov record NCT07557953 at 2026-07-30T16:19:36.906Z. Its registry update date was 2026-05-15, and PeptideScanner's reviewed identity mapping was cagrilintide.

PeptideScanner change date
August 8, 2026
Cited source date
May 15, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07220642

PeptideScanner retained ClinicalTrials.gov record NCT07220642 at 2026-07-30T16:19:03.066Z. Its registry update date was 2026-06-30, and PeptideScanner's reviewed identity mapping was cagrilintide.

PeptideScanner change date
July 31, 2026
Cited source date
June 30, 2026
Evidence lane
Clinical trials